Daiwa Securities Group Inc. Fibrogen Inc Transaction History

Daiwa Securities Group Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$13.27 - $17.73 $809 - $1,081	61 Added 19.24%	378 $6,000
Q3 2021 Nov 05, 2021	BUY	$10.18 - $26.64 $1,486 - $3,889	146 Added 85.38%	317 $3,000
Q4 2020 Feb 04, 2021	SELL	$37.09 - $48.97 $12,499 - $16,502	-337 Reduced 66.34%	171 $6,000
Q3 2020 Nov 02, 2020	BUY	$40.47 - $45.5 $647 - $728	16 Added 3.25%	508 $21,000
Q4 2019 Jan 31, 2020	SELL	$34.58 - $48.06 $1,798 - $2,499	-52 Reduced 9.56%	492 $21,000
Q1 2019 Apr 26, 2019	SELL	$42.83 - $59.91 $2,526 - $3,534	-59 Reduced 9.78%	544 $30,000
Q4 2018 Feb 05, 2019	BUY	$37.97 - $60.16 $5,695 - $9,024	150 Added 33.11%	603 $28,000
Q1 2018 May 02, 2018	BUY	$45.35 - $61.65 $20,543 - $27,927	453 New	453 $21,000

46.8M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $46.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

Stay updated on Daiwa Securities Group Inc. with notifications on news.